ERIC EVANS: Open Payments
NPI 1407808314 · GREENVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,307 in 54 payments from 9 companies in 2025. Trend: 2023 $3,994 · 2024 $1,775 · 2025 $1,307
Food & beverage: $1,129Education: $178
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $479 |
| Neurocrine BioSciences, Inc. | 9 | $275 |
| Alkermes, Inc. | 15 | $249 |
| Luye Pharma (USA) Ltd. | 2 | $146 |
| E.R. Squibb & Sons, L.L.C. | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: AUSTEDO XR, INGREZZA, ARISTADA, ERZOFRI EXTENDED-RELEASE, COBENFY, Qelbree, LYBALVI, REXULTI.
Industry payments across NC — which companies pay providers there.
